Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIa proof-of-concept study of IMD-1041 in COPD
2008-001889-81Phase 2Terminated
- Sponsor
- Institute of Medicinal Molecular Design, Inc.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of IMD-1041 in chronic obstructive pulmonary disease (COPD), sponsored by Institute of Medicinal Molecular Design, Inc. Primary endpoints: Reduction in selected systemic inflammatory biomarkers, Reduction in induced sputum inflammatory biomarkers and 1 more. Started Apr 2008; status: terminated.
02
Drugs
IMD-1041
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2008-001889-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001889-81.